SCHEMBL126680

SCHEMBL126680

CC(=O)CC[C@H](N)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.65
CYP1A2 P05177 2/20 0.65
GRM8 O00222 1/20 0.65
GRM6 O15303 1/20 0.65
GRIN2D O15399 1/20 0.65
GRIN3B O60391 1/20 0.65
GRIK1 P39086 1/20 0.65
GRM5 P41594 1/20 0.65
GRIA1 P42261 1/20 0.65
GRIA2 P42262 1/20 0.65
GRIA3 P42263 1/20 0.65
SLC1A3 P43003 1/20 0.65
SLC1A2 P43004 1/20 0.65
SLC1A1 P43005 1/20 0.65
GRIA4 P48058 1/20 0.65
GRIN1 Q05586 1/20 0.65
GRIN2A Q12879 1/20 0.65
GRIK2 Q13002 1/20 0.65
GRIK3 Q13003 1/20 0.65
GRIN2B Q13224 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1330943 1.00 GSR (0.65) GSRCYP1A2GRM8GRM6GRIN2D
SCHEMBL3867126 1.00 GSR (0.65) GSRCYP1A2GRM8GRM6GRIN2D
Bromide SCHEMBL29951435 0.98 GSR (0.62) GSRCYP1A2GRM8GRM6GRIN2D
Ammonia Solution, Strong SCHEMBL25334885 0.98 GSR (0.62) GSRCYP1A2GRM8GRM6GRIN2D
SCHEMBL26747924 0.86 GSR (0.56) GSRCYP1A2GRM8GRM6GRIN2D
SCHEMBL10279976 0.86 GSR (0.56) GSRCYP1A2GRM8GRM6GRIN2D
SCHEMBL27855469 0.85 GRM8 (0.65) GSRCYP1A2GRM8GRM6GRIN2D
SCHEMBL12516455 0.84 GSR (0.59) GSRCYP1A2GRM8GRM6GRIN2D
Glutamic Acid SCHEMBL184513 0.83 GRM8 (0.86) GSRCYP1A2GRM8GRM6GRIN2D
D-Glutamate SCHEMBL184512 0.83 GRM8 (0.86) GSRCYP1A2GRM8GRM6GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010771-A 6-Diazonium-5-oxo-norleucine derivative, preparation method and application 西北工业大学深圳研究院 2026-05-12 CN claimed
US-12552839-B2 Cyclic peptides for protection against respiratory syncytial virus VIROMETIX AG (CH) 2026-02-17 US claimed
CN-112689758-B Device and method for checking the effect of a drug on microorganisms 上海宜晟生物科技有限公司 2025-03-28 CN claimed
CN-119584992-A Antibody-drug conjugates comprising antibodies against human TROP2 and uses thereof 瑞嘉化学生物科学股份有限公司 2025-03-07 CN claimed
US-20240287143-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Universität Zürich (CH) 2024-08-29 US claimed
EP-4295866-A2 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Virometix AG (CH) 2023-12-27 EP claimed
CN-114805138-B Prodrugs of 6-diazo-5-oxo-L-norleucine, methods of making and uses thereof 中国科学院长春应用化学研究所 2023-10-10 CN claimed
EP-3638284-B1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS VIROMETIX AG (CH) 2023-08-30 EP claimed
CN-116531346-A Nanometer medicine for cisplatin-resistant tumor glutamine interference therapy and preparation method and application thereof 滨州医学院 2023-08-04 CN claimed
CN-116510024-A Composition, preparation method and application thereof 上海复东生物医药有限责任公司 2023-08-01 CN claimed
CN-116283402-A Fertilizer for relieving cotton boll period high temperature heat injury and preparation method and application thereof 台沃科技集团股份有限公司 2023-06-23 CN claimed
US-11680085-B2 Cyclic peptides for protection against respiratory syncytial virus VIROMETIX AG (CH) 2023-06-20 US claimed
US-20210101941-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Universität Zürich (CH) 2021-04-08 US claimed
EP-3638284-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Virometix AG (CH) 2020-04-22 EP claimed
CN-110891592-A Cyclic peptides for protection against respiratory syncytial virus 维罗米蒂克斯股份公司 2020-03-17 CN claimed
WO-2018229156-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS VIROMETIX AG (CH) 2018-12-20 WO claimed
EP-2856170-B1 METHODS FOR DIAGNOSING CHRONIC VALVULAR DISEASE NESTEC SA (CH) 2018-07-25 EP claimed
WO-2018112363-A1 METHODS OF TREATING CANCER USING PARABACTEROIDES EVELO BIOSCIENCES, INC. (US) 2018-06-21 WO claimed
EP-2036918-A1 PEPTIDE DERIVATIVE Vexon, Inc. (JP) 2009-03-18 EP claimed
US-20080009448-A1 Peptide Derivative VEXON, INC. (50%) (JP) 2008-01-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11680085-B2 Cyclic peptides for protection against respiratory syncytial virus VIP, LNPEP, CSTB GSR 1013/4885CYP1A2 4737/4885GRM8 3493/4885
US-20240287143-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS VIP, QPCT, QPCTL GSR 1793/4885CYP1A2 4833/4885GRM8 1335/4885
US-20210101941-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS QPCT, QPCTL, VIP GSR 1643/4885CYP1A2 4771/4885GRM8 1035/4885
US-12552839-B2 Cyclic peptides for protection against respiratory syncytial virus CTH, VIP, CXCL10 GSR 864/4885CYP1A2 4695/4885GRM8 157/4885
US-20080009448-A1 Peptide Derivative ARGLU1, NGLY1, NPR3 GSR 4547/4885CYP1A2 1409/4885GRM8 2265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.